Avedro initiated with an Overweight at JPMorgan. JPMorgan analyst Robbie Marcus started Avedro with an Overweight rating and $16 price target. The company’s KXL platform for corneal cross-linking represents the only FDA-approved treatment proven to stop or slow the progression of keratoconus, Marcus tells investors in a research note. He sees a “clear pathway” to multiple years of double-digit sales growth for Avedro.
https://thefly.com/landingPageNews.php?id=2876981
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.